NCT07333261 Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
| NCT ID | NCT07333261 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Susan Bal |
| Condition | Multiple Myeloma |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2026-02-09 |
| Primary Completion | 2031-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 25 participants in total. It began in 2026-02-09 with a primary completion date of 2031-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
Eligibility Criteria
Inclusion Criteria: 1. Age \> 18 years with no upper age limit 2. NDMM with indication for initiation of therapy diagnosed within last 12 months. Pretreatment parameters necessary for disease characterization and response assessment must be available. 3. Not eligible for ASCT by institutional criteria or deferring ASCT due to personal preference. 4. ECOG performance status 0-1 5. Adequate organ function Exclusion Criteria: 1. Known active or history of central nervous system (CNS) involvement of MM. 2. Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS or clinically significant amiloidosis. 3. Prior history of other malignancies 4. Uncontrolled infection Other protocol-defined Inclusion/Exclusion criteria apply.
Contact & Investigator
Susan Bal, MD
PRINCIPAL INVESTIGATOR
The University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT07333261 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07333261 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07333261 currently recruiting?
Yes, NCT07333261 is actively recruiting participants. Contact the research team at susanbal@uabmc.edu for enrollment information.
Where is the NCT07333261 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT07333261 clinical trial?
NCT07333261 is sponsored by Susan Bal. The principal investigator is Susan Bal, MD at The University of Alabama at Birmingham. The trial plans to enroll 25 participants.